Drug Search Results
More Filters [+]

ADG-152

Alternative Names: ADG-152, ADG152, ADG 152
Latest Update: 2021-12-22
Latest Update Note: Clinical Trial Update

Product Description

ADG152 is a novel CD20xCD3 TCE prodrug engineered using Adagene's SAFEbody technology to minimize or eliminate CRS and on-target/off-tumor toxicities. (Sourced from: https://ashpublications.org/blood/article/138/Supplement%201/1204/480432)

Mechanisms of Action: CD20 Antagonist,CD3 Inhibitor

Novel Mechanism: No

Modality: Bispecific Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Adagene
Company Location: JIANGSU F4 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ADG-152

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events